Primary Characteristics
It is of Synthetic origin.
It belongs to Factor Xa Inhibitor pharmacological group on the basis of mechanism of action.
Non-proprietary name: Rivaroxaban.
Pharmacokinetics
Absorption: Rivaroxaban has an oral bioavailability is 90% (±10%).
Distribution: Rivaroxaban has a volume of distribution is 50L. plasma protein binding is 92-95%.
Elimination: it is metabolised via hepatic, plasma half-life is 7-11 hours.
Advertisement
Indications
Rivaroxaban is primarily indicated in conditions like Venous thromboembolic disease.
Contraindications
Rivaroxaban is contraindicated in conditions like Hepatic disease, Hypersensitivity, Bleeding.
Dosage
Rivaroxaban's dosage details are as follows:
| Dose | Single Dose | Frequency | Route | Instructions |
|---|---|---|---|---|
| Adult Dosage | ||||
| 10 mg | 10 mg | Every 24h | PO | the initial dose should be taken 6-8hours after surgery if the dose is missed patient should take it immediately Can be taken with or without food |
| Paediatric Dosage (20kg) | ||||
| No data. | ||||
| Neonatal Dosage (3kg) | ||||
| No data. | ||||
Drug Interactions
Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Side Effects
The signs and symptoms that are produced after acute overdosage of Rivaroxaban are Bleeding .
Rivaroxaban is known to cause more or less tolerable side effects which are usually transient. These include Anemia, angina pectoris, Bleeding , cardiac ischemia, Chest pain, Dizziness, Dyspnea, Fever, Headache, increase GGT level, increase transaminase, Nausea, paleness, Peripheral edema, Renal failure, Shock symptoms, Syncope , Weakness.
Warnings / Precautions
Interference in Pathology
Rivaroxaban may interfere in the diagnosis of Clotting factors e.g PT, aPTT, HepTest are affected.
Available Brands
Drug Classification
- 1.10.2 — Anticoagulants/Platelet deaggregators